Effect of iNO in Patients With Submassive and Massive PE
Key facts
- Who runs it
- University of California, Los Angeles
- Where
- Los Angeles, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- 1 Jun 2026
- Expected to end
- 30 Jun 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- inhaled nitric oxide (iNO)
- Record updated
- 18 March 2026
- Why it stopped
- no sponsor support
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (19)Hide the full registry criteria
Who can take part
- Patient ≥ 18 years of age
- The patient or patient's surrogate decision maker must understand and sign the informed consent form (ICF)
- Hospitalized (Emergency Room (ER) or inpatient) with:
- Imaging (computed tomography pulmonary angiography (CTPA) or ventilation/perfusion (VQ) lung scan) proven acute pulmonary embolism (PE)
- PE meets the following intermediate risk PE criteria (or massive, see below):
- Troponin > .1 AND
- Imaging (computed tomography (CT) or transthoracic echocardiogram (TTE)) signs of RV compromise (at least 1 of the following):
- RV:LV>1 on TTE or CTPA OR RV dilation (TTE or CTPA OR RV dysfunction on TTE
- Massive PE
- Intensive care unit (ICU) level of care (Patient moving to ICU, ICU level of care in ER, or currently in ICU)
- Ability to comply with study protocol in investigator's judgement
Who cannot take part
- Patients already on iNO prior to study enrollment
- Known allergy to iNO
- Any serious medical condition of lab abnormality that, in the investigator's judgement, precludes the patient's safe participation in the study
- Pregnancy or breastfeeding
- Inability to administer iNO through current mode of O2 delivery (i.e. BiPAP)
- Active hemoptysis
- Methemoglobin reductase deficiency
- Unable to obtain consent or patient or patient surrogate decision maker declines
Where in United States
- Ronald Reagan UCLA Medical CenterLos Angeles, United States
About the trial
What the trial wants to find out
A single center study to evaluate the effect of inhaled nitric oxide (iNO) on pulmonary dynamics in patients presenting with imaging confirmed intermediate/submassive or massive pulmonary embolism (PE). The target enrollment is 20 subjects at Ronald Reagan UCLA Medical Center. PE patients undergoing catheter-based intervention will be administered iNO during their intervention and pulmonary hemodynamic measurement will be measured before, during, and after iNO administration (Invasive Cohort). Patients who are not undergoing catheter-based intervention will also be administered iNO and will have pulmonary hemodynamics, blood pressure, and heart rate measured non-invasively (Non-Invasive Cohort).
The 2 groups in the trial
- Interventional Radiology Arm (Invasive Cohort)Existing treatment, for comparison
Interventional radiology (IR) will perform a right heart catheterization (RHC) as part of a planned IR procedure. Bedside apical 4 chamber view (RV:LV ratio) will be recorded using an ultrasound device, and noninvasive RV data will be obtained with Edwards ClearSight system and Edwards EV1000 clinical platform. The Butterfly iQ+ (one possible ultrasound device which may be used) is a single-probe, whole-body ultrasound device. After initial measurements, inhaled nitric oxide (iNO) will be administered at 30 ppm for 3 minutes. The same measurements will be obtained/calculated before, during iNO administration, and after iNO has been withheld for 2 minutes.
Treatment: inhaled nitric oxide (iNO)
- Non-intervention Arm (Non-invasive Cohort)Existing treatment, for comparison
Vitals including O2 amount and modality, blood pressure, pressor name, dose, and rate will be recorded. If the patient is intubated, the name, dose, and rate of sedation and analgesia will be recorded. If the patient is not intubated, name and dose amount of sedation will be recorded. Arterial blood gas will be obtained if an A-line is placed. Bedside apical 4 chamber view will be recorded (RV:LV ratio) with an ultrasound device, and noninvasive RV data will be obtained with Edwards ClearSight system and Edwards EV1000 clinical platform. This data will be obtained before, during iNO administration, and after iNO has been withheld for 2 minutes.
Treatment: inhaled nitric oxide (iNO)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Study to Evaluate the Role of Inhaled Nitric Oxide (iNO) on Pulmonary Hemodynamics in Patients With Intermediate/Submassive and Massive Pulmonary Embolism (PE)
- Record updated
- 18 March 2026